

### AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides nucleobases in length and having a nucleobase sequence comprising an at least 8 consecutive nucleobase portion of SEQ ID NO: 64, wherein said compound nucleobase sequence of said oligonucleotide is 100% complementary to SEQ ID NO:17.

2. (Currently Amended) The compound of claim 1, wherein said oligonucleotide which is an antisense oligonucleotide.

3. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

4. (Original) The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

5. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

6. (Original) The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

7. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

8. (Original) The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

9. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10. (Canceled).

11. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. (Original) The composition of claim 11 further comprising a colloidal dispersion system.

13. (Currently Amended) The composition of claim 11 wherein the compound oligonucleotide is an antisense oligonucleotide.

14. (Previously Presented) A method of inhibiting the expression of BCL2-associated X protein in cells or tissues in vitro comprising contacting said cells or tissues with the compound of claim 1 so that expression of BCL2-associated X protein is inhibited.

15. (Previously Presented) The compound of claim 1 wherein the compound comprises ISIS 134323.

16. (Previously Presented) The compound of claim 1 wherein the compound consists of SEQ ID NO: 64.

17. (Previously Presented) The compound of claim 2 wherein the oligonucleotide comprises:

a gap segment consisting of linked deoxynucleotides;

a 5' wing segment consisting of linked nucleotides;

a 3' wing segment consisting of linked nucleotides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleotide of each wing segment comprises a modified sugar.

18. (Previously Presented) The compound of claim 17 wherein the oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleotides;

a 5' wing segment consisting of five linked nucleotides;

a 3' wing segment consisting of five linked nucleotides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleotide of each wing segment comprises a 2'-O-methoxyethyl sugar, and wherein each internucleoside linkage in said oligonucleotide is a phosphorothioate linkage.

19. (Previously Presented) The compound of claim 18, wherein said oligonucleotide is 20 nucleobases in length and consists of SEQ ID NO:64.